Piper Sandler upgraded Myriad Genetics (MYGN) to Overweight from Neutral with a price target of $12.50, up from $11.50. The stock is down more than 50% in the last six months and Myriad still has a leading position and high margins in markets that are consolidating around a “profitability paradigm,” the analyst tells investors in a research note. Piper believes the stock “has more than rebased” and the new CEO Sam Raha has a chance to reset the business, make strategic decisions and “provide reasonable expectations to match.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics price target lowered to $16 from $21 at Morgan Stanley
- Myriad Genetics price target lowered to $11.50 from $14 at Piper Sandler
- Myriad Genetics price target lowered to $11 from $13 at BofA
- Myriad Genetics Faces Financial Uncertainty Amid Potential Tax Law Changes
- Myriad Genetics Reports Strong Growth Amid Challenges
Questions or Comments about the article? Write to editor@tipranks.com